Regeneron Pharmaceuticals Inc. Makes New $1.05 Billion Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Regeneron Pharmaceuticals Inc. bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 4,444,445 shares of the biopharmaceutical company's stock, valued at approximately $1,045,822,000. Alnylam Pharmaceuticals accounts for about 95.5% of Regeneron Pharmaceuticals Inc.'s holdings, making the stock its largest holding. Regeneron Pharmaceuticals Inc. owned about 3.45% of Alnylam Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of ALNY. Huntington National Bank boosted its position in Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Larson Financial Group LLC boosted its position in Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 73 shares during the last quarter. R Squared Ltd acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at $33,000. OFI Invest Asset Management acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at $35,000. Finally, True Wealth Design LLC boosted its position in Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 153 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Remove Ads

Insider Transactions at Alnylam Pharmaceuticals

In other news, CMO Pushkal Garg sold 1,752 shares of the business's stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $251.00, for a total value of $439,752.00. Following the transaction, the chief marketing officer now directly owns 15,705 shares of the company's stock, valued at $3,941,955. The trade was a 10.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Phillip A. Sharp sold 11,250 shares of the company's stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. Insiders have sold 72,986 shares of company stock valued at $20,397,849 in the last three months. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY traded up $5.67 during trading on Tuesday, reaching $238.74. 603,109 shares of the company traded hands, compared to its average volume of 791,183. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The stock's 50 day moving average price is $254.64 and its two-hundred day moving average price is $260.93. The company has a market cap of $30.91 billion, a price-to-earnings ratio of -110.02 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analysts Forecast Growth

ALNY has been the subject of a number of research reports. Canaccord Genuity Group lifted their price objective on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a "buy" rating in a research report on Tuesday, February 18th. StockNews.com lowered Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, January 9th. Needham & Company LLC restated a "buy" rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. Piper Sandler restated an "overweight" rating and set a $296.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Finally, Sanford C. Bernstein cut their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a report on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $304.26.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.